The cross-sectional survey on COVID-19 vaccine hesitancy and it predictors among Chinese parents of 3–17 years aged children in Shenzhen City
More details
Hide details
Department of Obstetrics and Gynecology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen, Guangdong, China
School of Nursing, Health Science Centre, Shenzhen University, Shenzhen, Guangdong, China
School of Nursing, Southern Medical University, Guangzhou, Guangdong, China
Corresponding author
Xujuan Zheng   

Shenzhen University
Ann Agric Environ Med. 2022;29(1):120-125
Introduction and objective:
Vaccinations programs on 3–17 years aged children in China have been launched in some cities since July 2021; and comparative evaluations are important to push the programs forward. Therefore, this study is conducted to explore the COVID-19 vaccine hesitancy and it predictors among Chinese parents of 3–17 years aged children; and their willingness to vaccinate their child/children.

Material and methods:
A cross-sectional study was conducted based on the online survey; and 3484 participants were recruited in health centers of Shenzhen, China.

The prevalence of COVID-19 vaccine hesitancy was 20.7% among Chinese parents of 3–17 years aged children; and 2976 participants (89.0%) were reported to be willing or very willing to accept a COVID-19 vaccine for their child/children. Perceived trust degree of a COVID-19 vaccine (OR: 0.766), and perceived effectiveness of a COVID-19 vaccine (OR: 0.455) were negatively associated with vaccine hesitancy. Perceived risk degree of a COVID-19 vaccine (OR: 1.485) positively predicted vaccine hesitancy. Parents with a higher educational level (OR: 0.518) and working in public institution (OR: 0.741) had a lower level of vaccine hesitancy; whereas, parents with liberal professionals had a higher level of vaccine hesitancy (OR: 1.378).

These findings indicated that Chinese parents of 3–17 years aged children in Shenzhen City had a higher level of COVID-19 vaccine acceptability, compared with adults in Western counties. The significant factors of perceived trust degree, effectiveness, and risk degree of a COVID-19 vaccine, parents’ educational level and occupation could predict COVID-19 vaccine hesitancy. The research results can be useful in supporting the development of effective and targeted children COVID-19 vaccination campaigns in China and worldwide.

Ting Li and Xichenhui Qiu contributed equally for this manuscript
This study was funded by the General Program of Stable Support Plan for Universities in Shenzhen City (20200804101756002).
Chriscaden K. Impact of COVID-19 on People’s Livelihoods, Their Health and Our Food Systems. WHO, 2020. https://www. (access: 2021.11.13).
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20: 533–534.
WHO Coronavirus Disease (COVID-19) Dashboard. (access: 2021.11.22).
Public Health and Social Measures (PHSM). WHO, 2021. (access: 2021.11.22).
Qualls N, Levitt A, Kanade N, et al. CDC Community Mitigation Guidelines Work Group. Community Mitigation Guidelines to Prevent Pandemic Influenza—United States, 2017. MMWR Recomm Rep. 2017; 66: 1–34. 10.15585/mmwr.rr6601a1.
Gori D, Reno C, Remondini D, et al. Are We Ready for the Arrival of the New COVID-19 Vaccinations? Great Promises and Unknown Challenges Still to Come. Vaccines. 2021; 9: 173. 10.3390/vaccines9020173.
Fernandes N, Costa D, Costa D, et al. Predicting COVID-19 Vaccination Intention: The Determinants of Vaccine Hesitancy. Vaccines. 2021; 9: 1161.
COVID-19 vaccine tracker and landscape. WHO, 2021. (access: 2021.11.20).
Fan YJ, Chan KH, Hung IFN. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines. 2021; 9: 989.
Akel KB, Masters NB, Shih SF, et al. Modification of a Vaccine Hesitancy Scale for use in adult vaccinations in the United States and China. Hum Vaccin Immunother. 2021; 17(8):1–8.
Thunstrom L, Ashworth M, Finnoff D, et al. Hesitancy towards a COVID-19 vaccine and prospects for herd immunity. SSRN. 2020; 1–51. 10.2139/ssrn.3593098.
Randall T, Sam C, Tartar A, et al. More Than 108 Million Shots Given: Covid-19 Tracker. (access: 2021.11.08).
Lu J, Wen X, Guo Q, et al. Sensitivity to COVID-19 Vaccine Effectiveness and Safety in Shanghai, China. Vaccines. 2021; 9: 472.
Barello S, Nania T, Dellafiore F, et al. “Vaccine hesitancy” among university students in Italy during the COVID- 19 pandemic. Eur J Epidemiol. 2020; 1: 3. 10.1007/s10654-020-00670-z.
Fu C, Wei Z, Pei S, et al. Acceptance and preference for COVID-19 vaccination in health-care workers (HCWs). medRxiv. 2020,20060103. 10.1101/2020.04.09.20060103.
Khan YH, Mallhi TH, Alotaibi NH, et al. Threat of COVID-19 vaccine hesitancy in Pakistan: the need for measures to neutralizeleading narratives. Am J Trop Med Hyg. 2020; 103(2): 603–04.
MacDonald NE, Eskola J, Liang X. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015; 33(34): 4161–64.
Di Martino G, Di Giovanni P, Di Girolamo A, et al. Knowledge and Attitude towards Vaccination among Healthcare Workers: A Multicenter Cross-Sectional Study in a Southern Italian Region. Vaccine. 2020; 8: 248.
Karafillakis E, Dinca I, Apfel F, et al. Vaccine hesitancy among healthcare workers in Europe: A qualitative study. Vaccine. 2016; 34: 5013–5020.
Reno C, Maietti E, Fantini MP, et al. Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy. Vaccine. 2021; 9: 378.
World Health Organization. Ten Threats to Global Health in 2019. (access: 2021.11.08).
MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33: 4161–4164. 10.1016/j.vaccine.2015.04.036.
The COVID-19 vaccine available for ages 3–17 is coming. (access: 2021.11.20).
Bell S, Clarke R, Mounier-Jack S, et al. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine. 2020; 38: 7789–7798.
Anderson EJ, Campbell JD, Creech CB, et al. Warp speed for COVID-19 vaccines: Why are children stuck in neutral? Clin Infect Dis. 2020; 73: 336–340. 10.1093/cid/ciaa1425.
Rapid Literature Review on Motivating Hesitant Population Groups in Europe to Vaccinate. (access: 2021.11.13).
Zhang XT, Wen D, Liang J, et al. How the public uses social media wechat to obtain health information in china: a survey study. BMC Med Inform Decis. 2017; 17(Suppl 2): 66.
Machida M, Nakamura I, Kojima T, et al. Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic. Vaccine. 2021; 9: 210. 10.3390/vaccines9030210.
Barello S, Nania T, Dellafiore F, et al. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. Eur J Epidemiol. 2020; 35: 781–783. 10.1007/s10654-020-00670-z.
Gagneux-Brunon A, Detoc M, Bruel S, et al. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross-sectional survey. J Hosp Infect. 2021; 108: 168–173.
Murphy J, Vallieres F, Bentall RP, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021; 12: 29.
Neumann-Bohme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020; 21: 977–982. 10.1007/s10198-020-01208-6.
Malik AA, McFadden SM, Elharake J, et al. Determinants of COVID-19 Vaccine Acceptance in the US. E Clinical Medicine. 2020; 26: 100495.
Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults. Ann Intern Med. 2020; 173: 964–973. 10.7326/M20-3569.
Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 Vaccine among Adults in the United States: How Many People Would Get Vaccinated? Vaccine. 2020; 38: 6500–6507. 10.1016/j.vaccine.2020.08.043.
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396: 479–488.
Journals System - logo
Scroll to top